Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoclopramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 5/20 | 0.95 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.95 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.95 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.95 |
| ▸ | DRD3 | P35462 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | HTR2B | P41595 | 2/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.95 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | HTR3B | O95264 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | MPO | P05164 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | DRD4 | P21917 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoclopramide SCHEMBL133509 | 1.00 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL18614363 | 1.00 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL6263013 | 1.00 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL5012583 | 1.00 | RAB9A (0.98) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL30571110 | 0.99 | RAB9A (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL205200 | 0.99 | RAB9A (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL678940 | 0.99 | RAB9A (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL9802884 | 0.98 | RAB9A (0.93) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL18629 | 0.98 | HTR4 (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A | |
| Metoclopramide SCHEMBL28222039 | 0.98 | HTR4 (1.00) | RAB9AHTR4CYP2D6CYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276139-A1 | METHODS OF INTRANASAL METOCLOPRAMIDE DOSING | EVOKE PHARMA, INC. | 2020-09-03 | — | — | US | disclosed |
| EP-3681573-A1 | METHODS OF INTRANASAL METOCLOPRAMIDE DOSING | Evoke Pharma, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019051366-A1 | METHODS OF INTRANASAL METOCLOPRAMIDE DOSING | EVOKE PHARMA, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-1429787-A1 | ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF RESTLESS LIMB SYNDROME AND PERIODIC LIMB MOVEMENT DISORDER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030092759-A1 | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003026676-A1 | ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF RESTLESS LIMB SYNDROME AND PERIODIC LIMB MOVEMENT DISORDER | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092759-A1 | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder | EPM2A, GRIN2A, GABRE | HTR4 953/4885HTR3A 364/4885DRD2 106/4885 |
| US-20200276139-A1 | METHODS OF INTRANASAL METOCLOPRAMIDE DOSING | MLNR, MLN, MTNR1B | HTR4 24/4885HTR3A 17/4885DRD2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.